Minerva Neurosciences, Inc.
NERVHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframePart of the healthcare sector, Minerva Neurosciences, Inc. (NERV) is listed under Biotechnology. The company carries a $109.8M market cap, placing it firmly in the micro-cap category. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.
Market Cap
$109.8M
Beta
-0.12
P/E (TTM)
—
P/E (Fwd)
-5.48
EPS (TTM)
$-34.75
EPS (Fwd)
$-0.42
ROE
—
ROA
-28.4%
Cash
$75.3M
Total Debt
$60.0M
Free CF
-$8.9M
52W Change
-51.1%
Annual Financials
Cash vs Debt
Where NERV stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, NERV finished 51.87% below its 150-day moving average ($4.82) and 53.51% below its 200-day moving average ($4.99). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NERV overbought or oversold?
At the October 20, 2026 close, NERV's RSI(14) was 17.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Minerva Neurosciences, Inc. holds $75.3M in cash against $60.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$8.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time.
With a beta below 0.7, Minerva Neurosciences, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing NERV's risk profile alongside its fundamentals and technical indicators provides a more complete picture.